A systematic review finds low-dose atropine is consistently cost-effective or cost-saving for slowing myopia progression in children, with lifetime savings driven by avoided high-myopia complications.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.